ATOR 1144
Alternative Names: ATOR-1144Latest Information Update: 28 Nov 2022
At a glance
- Originator Alligator Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; TNFRSF18 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in Sweden (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Solid-tumours in Sweden (Parenteral)
- 07 Apr 2020 ATOR 1144 is available for licensing as of 07 Apr 2020. www.alligatorbioscience.com